Pulsatile administration of the EGF receptor inhibitor gefitinib (Iressa, ZD 1839) is significantly more effective than continuous dosing for sensitizing tumors to Taxol Meeting Abstract


Authors: Solit, D. B.; She, Y.; Moasser, M.; Hudis, C.; Kris, M.; Scher, H.; Rosen, N.; Sirotnak, F. M.
Abstract Title: Pulsatile administration of the EGF receptor inhibitor gefitinib (Iressa, ZD 1839) is significantly more effective than continuous dosing for sensitizing tumors to Taxol
Meeting Title: 2003 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Journal Title: Clinical Cancer Research
Volume: 9
Issue: 16 Pt. 2
Meeting Dates: 2003 Nov 17-21
Meeting Location: Boston, MA
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2003-12-01
Start Page: 6089s
Language: English
ACCESSION: WOS:000187467300084
PROVIDER: wos
PUBMED: 14712828
Notes: Meeting Abstract: #A83 -- Poster Session A -- Source: Wos
MSK Authors
  1. Mark M Moasser
    55 Moasser
  2. Clifford Hudis
    839 Hudis
  3. Neal Rosen
    356 Rosen
  4. David Solit
    431 Solit
  5. Yuhong She
    31 She
  6. Howard Scher
    816 Scher
  7. Mark Kris
    597 Kris
  8. Francis M Sirotnak
    112 Sirotnak